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ABSTRACT.
Purpose: To help differentiate CLN3 (Batten) disease, a devastating childhood
metabolic disorder, from the similarly presenting early-onset Stargardt disease
(STGD1). Early clinical identification of children with CLN3 disease is essential
for adequate referral, counselling and rehabilitation.
Methods: Medical chart review of 38 children who were referred to a specialized
ophthalmological centre because of rapid vision loss. The patients were subsequently
diagnosedwith eitherCLN3disease (18 patients) or early-onset STGD1 (20 patients).
Results: Both childrenwhowere later diagnosedwithCLN3 disease, as childrenwho
were later diagnosed with early-onset STGD1, initially presented with visual acuity
(VA) loss due to macular dystrophy at 5–10 years of age. VA in CLN3 disease
decreased significantly faster than in STGD1 (p = 0.01). Colour vision was often
already severely affected in CLN3 disease while unaffected or only mildly affected in
STGD1.Optic disc pallor on fundoscopyand anabnormal nerve fibre layer onoptical
coherence tomography were common in CLN3 disease compared to generally
unaffected in STGD1. In CLN3 disease, dark-adapted (DA) full-field electroretino-
gram (ERG) responses were either absent or electronegative. In early-onset STGD1,
DA ERG responses were generally unaffected. None of the STGD1 patients had an
electronegative ERG.
Conclusion: Already upon presentation at the ophthalmologist, the retina in
CLN3 disease is more extensively and more severely affected compared to the
retina in early-onset STGD1. This results in more rapid VA loss, severe colour
vision abnormalities and abnormal DA ERG responses as the main differenti-
ating early clinical features of CLN3 disease.
Key words: Batten disease – childhood retinal dystrophy – CLN3 disease – deep phenotyp-
ing – early recognition – early-onset STGD1
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The majority of children presenting with
vision loss, who on ocular examination
prove to have macular dystrophy, suffer
from early-onset Stargardt disease
(STGD1) (OMIM #248200), which is
a retina-only disease (Lambertus et al.
2015). A significant minority, however,
actually suffer from CLN3 disease (Bat-
ten disease) (OMIM #204200), which is
a devastating metabolic disease impact-
ing both retina and brain, generally
limiting life expectancy to the early
twenties (Mole & Cotman 2015). At
disease onset, patients with CLN3 dis-
ease generally present with rapid loss of
vision as their main or only complaint
at the ophthalmologist (Bohra et al.
2000; Ouseph et al. 2016). Early distinc-
tion between CLN3 disease and early-
onset STGD1 is essential to tailor
counselling, minimizing both a diagnos-
tic odyssey in those with CLN3 disease,
and unnecessary concerns in those with
early-onset STGD1. However, the ini-
tial close resemblance between these
disorders complicates differentiation in
ophthalmological practice.
In more frequent disorders, repeated
exposure facilitates a pattern recogni-
tion process that allows clinicians to
identify differentiating features that aid
a correct and early diagnosis. The
rareness of particularly CLN3 disease
precludes this naturally occurring
learning curve. We hypothesized that
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recognition of a rare disorder could be
improved by an in-depth analysis of all
phenotypic abnormalities observed—
also known as deep phenotyping—
compared to an apparently similar,
but more frequent, disorder to identify
differentiating phenotypic abnormali-
ties (Robinson 2012). By doing so,
pattern recognition could be made
available for rare disorders as well.
In this study, we aimed to delineate
defining clinical characteristics of
CLN3 disease as compared to early-
onset STGD1 at presentation at the
ophthalmologist. The differentiating
characteristics identified in this study
could aid ophthalmologists in the early
recognition of CLN3 disease, minimiz-
ing a diagnostic odyssey.
Materials and Methods
Patients
We retrieved the medical records of
those patients referred to Bartimeus for
the ophthalmological assessment of
their vision loss, who were at a later
stage diagnosed with either CLN3 dis-
ease or early-onset STGD1 (Lambertus
et al. 2015; Mole & Cotman 2015).
Diagnosis was considered confirmed
upon identification of either bi-allelic
mutations in ABCA4 (in the case of
early-onset STGD1) or bi-allelic muta-
tions in CLN3 (in the case of CLN3
disease). Of note, in the case of CLN3
disease, genetic confirmation has only
been possible since 1995 (International
Batten Disease Consortium 1995).
Therefore, for patients diagnosed before
or around this time, we considered the
presence of vacuolated lymphocytes—if
found in an individual with retinal
dystrophy, pathognomonic for CLN3
disease, sufficient proof (Anderson et al.
2005; Kuper et al. 2020).
Ophthalmological centre
Bartimeus is the national tertiary refer-
ral centre for rare ophthalmic diseases
in children. Children suspected of an
unusual ophthalmic disease in general
practice are generally quickly referred
to Bartimeus for an extensive ophthal-
mological assessment. Since this assess-
ment occurs usually within two to four
weeks after referral, we regarded this
examination as ‘upon presentation’.
A waiver of requirement for ethical
review was granted by The Medical
Ethical Research Committee of the
University Medical Center Utrecht.
Data collection
From the clinical history, we retrieved
the onset of vision loss and the pres-
ence of additional ophthalmological
complaints (specifically night vision
problems, photophobia) upon presen-
tation. We regarded the moment at
which the first signs of rapid vision loss
were noticed as the time-point of onset
(T = 0). If the onset was not reported,
then the first rapid vision loss-related
doctor visit was regarded as T = 0.
From the validated clinical assess-
ments, we retrieved visual acuity
(VA), colour vision, and contrast sen-
sitivity. To analyse vision loss over
time, we included all VA measurements
available prior to, around, and follow-
ing the first ophthalmological assess-
ment at Bartimeus. We retrieved the
best corrected VA (BCVA) of both eyes
(VODS) from each measurement. If the
VA of the right eye (VOD) and the VA
of the left eye (VOS) were described
only separately, we used the BCVA in
the better eye. Regarding colour vision,
we included the severity of a colour
vision deficiency if the Hardy Rand
Rittler (HRR) test was included in the
test battery. From ophthalmoscopy, we
retrieved imaging [fundus photogra-
phy, fundus autofluorescence (FAF),
and optical coherence tomography
(OCT)], and full-field electroretinogra-
phy (ffERG). If available, we collected
the original images and graphs in
addition to the descriptive conclusion
of these assessments. From the globally
tested assessments, we retrieved periph-
eral visual field results (examined with
confrontational techniques because of
the young age of the patients).
Fundus photography and FAF were
made using the Canon CX-1 camera.
Optical coherence tomography (OCT)
images were obtained with RT-Vue
(Optovue, Fremont, CA, USA). Full-
field ERG recordings were performed
in accordance with the guidelines of the
International Society for Clinical Elec-
trophysiology of Vision (ISCEV)
(McCulloch et al. 2015). To obtain
the responses, Dawson–Trick–Litzkow
(DTL) corneal electrodes were used.
For flash stimulation, an Espion E3
System with ColorDome Stimulator
(Diagnosys LLC, Cambridge, UK)
was used. From the extended ISCEV
series measured at Bartimeus, we
extracted the light adapted (LA), 3.0
and 30Hz flicker responses and the
dark adapted (DA) 0.01 and 3.0
responses (Brouwer et al. 2019).
All ophthalmological examinations
(with the exception of VA tests per-
formed before t = 0) were performed at
the same day at the Bartimeus institute.
Data analysis
Due to the retrospective nature of the
study, VA was measured using different
methods and thus reported in different
units. To be able to analyse VA loss for
all patients per diagnosis combined,
we converted all VA measurements
into decimals. We used multilevel
modelling—that accounts for imbal-
anced repeated measurements—to
assess the velocity of the vision loss per
diagnosis (Snijders & Bosker 2012). We
analysed the velocity of the vision loss
during the complete follow-up (starting
from t = 0) in general, as during the first
year of follow-up specifically.
Of all analyses, except for the OCT
analyses of the inner retina described
below, blinding was not necessary since
we retrieved and analysed the original
descriptive conclusions of these assess-
ments when the underlying diagnosis
was not yet known. In addition to the
original descriptive conclusions of the
OCT scans, an additional retrospective
analysis of the OCT scans was per-
formed. Optical coherence tomography
(OCT) scans were analysed by com-
parison of the MM6 scan capturing the
foveal region (manually extracted from
the 12 radial line scans by WK). The
MM6 scan was used based on the
recognition that the more commonly
used line scans due to eccentric fixation
often failed to capture the foveal
region. Due to this technical limitation,
a reliable quantitative analysis of the
MM6 OCT scans was not possible.
Alternatively, the OCT scans of n = 9
CLN3 disease patients and n = 13
early-onset STGD1 patients were sub-
jected to a qualitative assessment of the
inner retina/nerve fibre layer (NFL) by
three experienced ophthalmologists
(MvS, JWP, and MvG) who were
blinded for the underlying diagnosis.
All three assessors were asked to clas-
sify the NFL of each OCT scan as
normal—doubtfully (ab)normal—or
abnormal. This assessment was tabu-




For multilevel modelling, MLwiN ver-
sion 3.0.1 was used to investigate lon-
gitudinal changes in VODS over time
(Centre for Multilevel Modelling,
University of Bristol, Bristol, UK).
An advantage of multilevel modelling
over the traditional repeated-measure-
ment approach is that all of the avail-
able results can be incorporated within
the analysis, even if the number of
measurements varies between the
patients because of missing data,
assuming that the missing data are
random. A 2-level multilevel structure
was used; level 1 represented repeated
measures within participants, level 2
represented differences among patients.
The predictor ‘years since onset’ was
entered into the model to find the best
model fit. The model fit was evaluated
by comparing the deviance (ln  2 log-
likelihood) of the empty model with the
final model.
The differences in age at onset, VA at
onset and vision loss velocity (as denom-
inated by the multilevel equation)
between CLN3 disease and early-onset
STGD1 were calculated using the
unpaired two-tailed t test in GRAPHPAD
PRISMversion8.0.1 (GraphPadPrism,San
Diego, CA, USA). p-Values below 0.05
were considered statistically significant.
Results
Between 1987 and 2019, a total of 38
patients were referred to a specialized
ophthalmological centre because of
rapid loss of vision, who were subse-
quently diagnosed with either CLN3
disease (n = 18) or early-onset STGD1
(n = 20) (Table S1 and S2).
Vision loss
Upon ophthalmological assessment,
patients who were later diagnosed with
CLN3 disease (from hereafter referred
to as patients with CLN3 disease),
reported a somewhat earlier onset of
vision loss (mean age at onset of
6.4 years, range 5–8 years) than
patients with early-onset STGD1
(mean age at onset of 7.5 years, range
5–10 years, p = 0.009). In addition,
there was a trend towards a worse VA
at CLN3 disease presentation (mean
VODS of 0.2 (comparable to 6/30 in
Snellen (m) ratios) in CLN3 disease
compared to mean VODS of 0.3 (com-
parable to 6/19 in Snellen (m) ratios) in
STGD1, p = 0.12). However, given
their clinically significant overlap, nei-
ther age at onset nor VODS at presen-
tation allowed to differentiate between
early-onset STGD1 or CLN3 disease.
The subsequent course of vision loss, in
contrast, did discriminate CLN3 dis-
ease from early-onset STGD1 (Fig. 1).
Already within the first year after
vision loss onset, VA decreased in
CLN3 disease significantly faster
(VODS1yr = 0.267–0.259*part of the
year since onset) than in early-onset
STGD1 (VODS1yr = 0.411–0.357*part
of the year since onset) (p = 0.01).
Colour vision
Systematic assessment revealed that the
severity of colour vision deficiency
allowed to distinguish most patients
with CLN3 disease from those with
early-onset STGD1. Normal colour
vision was only seen in patients with
early-onset STGD1. Conversely,
severely affected colour vision—most
pronounced in red-green (RG) colour
vision but also in tritan colour vision—
indicated that the patient was suffering
from CLN3 disease (Fig. 2 and
Table S1). Of note, in the only one
(male) early-onset STGD1 patient
exhibiting a severe RG colour vision
deficiency, a highly ordered Farns-
worth D15 pattern was found sugges-
tive of a congenital deutan deficiency as
relatively commonly occurring in males
(Table S1) (Simunovic 2010).
Fundoscopy
Macular pigmentary changes were pre-
sent in all CLN3disease patients and the
majority of early-onset STGD1 patients
(n = 17/20), but the presence of optic
disc pallor and attenuated vessels
proved somewhat more discriminatory:
their presence was observed in the
majority (n = 12/17 and n = 15/17,
respectively) of patients with CLN3
disease, being rare in patients with
early-onset STGD1 (n = 2/20 and
n = 2/19, respectively) (Fig. 3,
Table S1).Of note, as in previous studies
on the early-onset type of STGD1,
typical STGD1 fundus abnormalities—
that is irregular yellow-white posterior
fundus flecks—were only rarely seen in
our early-onset STGD1 cohort, under-
scoring the difficulty to distinguish
CLN3 disease from early-onset STGD1
in this initial phase (Lambertus et al.
2015; Bax et al. 2019).
Optical coherence tomography
Patients with CLN3 disease and
patients with early-onset STGD1 pre-
sented with macular atrophy on OCT.
The optic disc pallor observed on
fundoscopy suggested a CLN3 dis-
ease-specific early involvement of the
inner retina. To further explore this
hypothesis, we used the OCT scans to
assess the different retinal layers. As
expected, the outer photoreceptor
related layers were severely affected in
both CLN3 disease and early-onset
STGD1. When focusing on the inner
retina, the NFL was indeed often
regarded abnormal in CLN3 disease
but regarded normal in early-onset
STGD1 (Fig. 3; Table 1).
Electroretinogram
In all CLN3 disease patients who
underwent visual electrophysiology
Fig. 1. Vision loss course in CLN3 disease and
early-onset STGD1. Visual acuity measurements
in CLN3 disease compared to early-onset Star-
gardt disease (STGD1). Velocity coefficient cal-
culations confirm similar VODS around
presentation but subsequently a significantly
faster decrease of visual acuity in CLN3 disease
(VODSoverall = 0.347–0.151*years since onset)
compared to early-onset STGD1 (VODSover-
all = 0.347–0.151*years sinceonset;p = 0.02) for
the complete follow-up period as shown in
figure). In both disease cohorts, VOD = VOS.
3
Acta Ophthalmologica 2020
testing (n = 13), the DA ERG was
described as markedly abnormal. In
n = 7 CLN3 disease patients, we could
retrieve the raw ERG responses to
further zoom in on the different
responses. In these, DA 0.01 responses
were severely reduced or absent. The
DA 3.0 bright flash responses showed a
b-wave which was much smaller than
the a-wave, also called an
electronegative ERG. In addition, the
photoreceptor-driven a-wave was
reduced in n = 4/7 patients. These
results confirm that inner retinal dys-
function occurs (as represented in the
b-wave) very early in CLN3 disease, in
some patients preceding deterioration
of the photoreceptors (as represented
in the a-wave) (Audo et al. 2008).
While the DA ERG was severely
reduced and electronegative in all
CLN3 disease patients, the DA
responses were unaffected (n = 8/11)
or only mildly reduced (n = 3/11) in
early-onset STGD1. None of the early-
onset STGD1 patients had an elec-
tronegative bright flash ERG (Fig. 4
and Table S1).
Of note, in our analysis, the LA
ERG did not always discriminate
CLN3 disease from early-onset
STGD1, as it was within normal limits
not only in 6 STGD1 patients, but also
in 1 CLN3 disease patient. Thus, the
DA ERG was necessary to distinguish
CLN3 disease and early-onset STGD1
without any doubt.
Multidimensional analysis of retinal
involvement in CLN3 disease compared
to early-onset STGD1
Based on the ophthalmological test
results, CLN3 disease and early-onset
STGD1 may seem very similar at
presentation (Fig. 5A), but can actu-
ally be distinguished clearly both on
the extensiveness of retina involvement
—that is the different components
affected—as on the degree to which
the different components were affected
(Fig. 5B).
Discussion
In this study, we explored whether we
could aid the ophthalmologist to dif-
ferentiate between a devastating meta-
bolic disorder and a retina-only
disease, despite their similar clinical
presentation. To the best of our knowl-
edge, we provide the most extensive
overview of the ophthalmological char-
acteristics early in CLN3 disease
described so far. Previous reports on
ocular abnormalities in CLN3 disease
generally discussed either relatively old
patients years after diagnosis or small
patient numbers, without or with only
few control patients with an isolated
retinal disease (Eksandh et al. 2000;
Hainsworth et al. 2009; Dulz et al.
2016; Hansen et al. 2016; Preising et al.
2017; Wright et al. 2019).
Rapid vision loss in a young child
may be caused by a number of diseases,
including optic neuropathies, intracere-
bral tumours, and retinal dystrophies.
In the case of a child with CLN3
disease, however, an ophthalmologist
will identify macular degeneration as
the primary cause of vision loss,
Fig. 2. Severity of colour vision deficiency around diagnosis in CLN3 disease and early-onset
STGD1. Red-green and tritan colour vision deficiency in n = 7 CLN3 disease patients and n = 14*
early-onset STGD1 patients tested with (at least) the HRR around diagnosis. *Excluded from this
figure is one (male) early-onset STGD1 patient with a suspected co-occurring congenital colour
vision deficiency (see also Table S1 and S2).
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because of the abnormalities seen on
funduscopy and OCT. Since our study
focuses specifically on patients with
macular degeneration presenting
around the age of 6 years, early-onset
STGD1 is the main disorder in the
differential diagnosis of CLN3 disease
(or the other way around).
Using a deep phenotyping approach,
we unveiled that compared to early-
onset STGD1, already in this early
stage of the disease, the retina in CLN3
disease is affected more extensively
(involving both cones and rods, as
optic nerve associated layers) and more
severely, resulting in several consistent
clinical and electrophysiological differ-
entiating features of CLN3 disease.
Three of these features most clearly
aided us to distinguish CLN3 disease
from early-onset STGD1: dramatically
rapid loss of vision, severe colour
vision deficiency (both indicative of
severe cone involvement) and absent
or electronegative DA ERG responses
(indicative of severe rod and optic
nerve involvement). The ability to rec-
ognize a rare disorder such as CLN3
disease on clinical characteristics only
is essential for speedy referral to a
metabolic paediatrician, and for ade-
quate rehabilitation, especially since
(untargeted) genetic analysis is not
always available or desirable. Patients
with CLN3 disease often already face
learning problems from disease presen-
tation requiring more than practical
adjustments for their visual impairment
alone (Spalton et al. 1980; Kuper et al.
2018).
By making the implicit explicit, our
approach has made pattern recognition
of the differentiating features of a rare
retinal dystrophy available to the clin-
ical practice in various contexts. We
were able to show that while the VA
itself may not be clearly different
between CLN3 disease and early-onset
STGD1 at presentation, the velocity of
the vision loss clearly is different—
already within the first year of follow-
up. Thus, in circumstances when refer-
ral to a specialized centre is not yet
possible, re-examining VA within a few
months will already help to determine
the probability of CLN3 disease as the
underlying diagnosis. Next, we argue




Fig. 3. Fundoscopy, and optical coherence tomography (OCT) around diagnosis in CLN3 disease and early-onset STGD1. Representative
fundoscopy (A), fundus autofluorescence (FAF) (B) and OCT (C), from n = 1 CLN3 disease patient (CLN3-5) and n = 1 early-onset STGD1 patient
(STGD1-18) (see Table S2) around presentation compared to n = 1 age-matched healthy control. Of note, due to eccentric fixation in both the CLN3
disease and early-onset STGD1 patients, line scans often did not capture the macula and while (one of the radial) MM6 image(s) did, often the retina
was not centered so clearly as seen in the early-onset STGD1 patient.
Table 1. Qualitative assessment of the nerve
fibre layer on optical coherence tomography









CLN3, N = 9
Normal 3 4
Doubt 3 1 7
Abnormal 3 4 2
STGD1, N = 13
Normal 10 10 11
Doubt 2 1
Abnormal 1 2 2
Qualitative assessment of the NFL performed
by three independent assessors (experienced
ophthalmologists) in n = 9 CLN3 disease and
n = 13 early-onset STGD1 radial MM6 OCT
scans made around diagnosis.
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with a test that specifies the severity of
a colour vision deficiency, such as the
HRR. Our results indicate that in most
children with vision loss due to macu-
lar atrophy, the probability of CLN3
disease as the underlying diagnosis can
already reliably be determined based
on the severity of a colour vision
deficiency. Finally, although it is more
invasive than most of the other tests,
our results clearly emphasize the rele-
vance of the ERG. Importantly, to
distinguish between CLN3 disease and
early-onset STGD1, a dark-adapted
ERG must be included. This was in
our study most strikingly exemplified
by the one CLN3 disease patient with
only a moderate (red-green) colour
vision deficiency and an unaffected
light adapted ERG in whom thus only
the—electronegative—dark-adapted
ERG responses were clearly outside the
range of early-onset STGD1 and
within the range of CLN3 disease. We
advise to perform the ERG in these
(young) children—who may in the case
of CLN3 disease already suffer from
subtle cognitive and/or behavioural
problems—in a specialized centre to
maximize the chance to get (reliable)
results (Spalton et al. 1980; van Gen-
deren et al. 2006; Kuper et al. 2018).
The apparent early involvement of
the inner retina and optic nerve in
CLN3 disease not only aids clinical
recognition and understanding, but
may also provide a clue towards under-
standing the function of the CLN3
protein, which has to date remained
enigmatic. Early optic nerve atrophy is
rare in most retinal dystrophies, but
relatively common in mitochondrial
disorders (Carelli et al. 2004). In
CLN3 disease, the predominant com-
ponent of the accumulated storage
material is the subunit c of mitochon-
drial F0 ATP synthase, a major com-
ponent of the inner mitochondrial
membrane. It has been postulated that
the CLN3 protein functions in a speci-
fic part of mitochondrial turnover.
When the CLN3 protein is deficient,
particularly those areas that require a
highly efficient mitochondrial turnover
—such as the optic nerve associated
layers—might deteriorate. Cln3 was
found to primarily localize to the inner
retina layers in mice and when deficient
optic nerve atrophy was an early fea-
ture, but ongoing difficulties with
Fig. 4. Light adapted and dark adapted ERG responses around diagnosis in CLN3 disease and early-onset STGD1. Dark adapted (DA 0.01, 3.0) and
light adapted (LA 3.0 and 30 Hz flicker) full-field ERG responses in n = 7 CLN3 disease patients and n = 11 early-onset STGD1 patients examined
around presentation compared to n = 1 age-matched healthy control. In the lower row, the composite DA 3.0 responses are shown.
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CLN3 antibody specificity preclude
definite conclusions on CLN3 location
and function (Katz et al. 1997; Sap-
pington et al. 2003; Weimer et al. 2006;
Nelson et al. 2017).
The extensive nature of the current
study allowed us to gain new insights,
yet still with some limitations. First, the
eccentric fixation and limited coopera-
tion of the children led us to use MM6
OCT images in this study. While very
useful to identify retinal dystrophy
with macular atrophy, these images
are less useful for an in-depth and
quantitative analysis of retinal layers in
these children. This may explain why
we did not corroborate a CLN3 dis-
ease-specific macular striation pattern
(Dulz et al. 2016; Wright et al. 2019).
Although there were some differences
between the three assessors in this
study, they did point towards an
apparent CLN3 disease-specific early
inner retina/NFL involvement (Preis-
ing et al. 2017). Second, we previously
described a subtle, but measurable
early onset of neurologic decline in
CLN3 disease (Kuper et al. 2018;
Kuper et al. 2019). Possibly, these early
learning and/or behavioural difficulties
contribute to less effective coping
strategies when vision gets lost and
thus an earlier presentation to the
ophthalmologist. In the present study,
we did not find any statistically signif-
icant evidence to support this notion,
but patients with CLN3 disease did
present at a slightly earlier age and with
a slightly worse VA than patients with
early-onset STGD1. To what degree
the early subtle neurologic impairments
impact the results of the (other) oph-
thalmologic assessments, particularly
colour vision and (peripheral) field
vision, is difficult to determine with
certainty. Finally, since this study is
focused on the differentiating charac-
teristics of CLN3 early in the disease
course, we did not include follow-up
measurements of the different assess-
ments, except for VA. Extensive visual
function testing and imaging are gen-
erally not repeated in CLN3 disease,
because of the rapidly progressive
vision loss and the current lack of
consequences for therapy. However,
when retina-targeting treatments will
arrive, longitudinal assessments of ocu-
lar changes in CLN3 disease will
become more relevant.
The phenotype of CLN3 disease is
distributed among a spectrum. While
most patients suffer from classical
CLN3 disease at the severe end of the
spectrum, protracted phenotypes have
been described as well (Mole & Cot-
man 2015; Kuper et al. 2018). In
protracted CLN3 disease, neurodegen-
eration may be delayed, but the retinal
phenotype is similar as in classical
CLN3 disease underscoring the impor-
tance of CLN3 in the retina (Kuper
et al. 2018). Interestingly, recent
research has revealed a new phenotypic
entity at the mild end of the phenotypic
spectrum, named CLN3 associated
(isolated) retinal degeneration, in
which neurodegeneration may never
occur at all, and which has a different
retinal phenotype as well (Wang et al.
2014; Ku et al. 2017; Kuper et al.
2017). Whereas in classical and pro-
tracted CLN3 disease, the retinal phe-
notype is characterized by a cone-rod
dystrophy with childhood onset rapidly
deteriorating to blindness, in the
CLN3-retina-only phenotype rather a
rod-cone dystrophy is seen with ado-
lescence-adult onset more slowly pro-
gressing over years to decades.
Whereas the contents of our study
may only be applicable to classical up
to and including protracted CLN3
disease, the approach of our study
may similarly be used to improve
recognition and understanding of
CLN3-associated retinal degeneration.
In conclusion, this study may aid
clinicians in differentiating between
two rare but clinically relevant disor-
ders of the retina—CLN3 disease and
early-onset STGD1—based on their
Fig. 5. Multidimensional analysis of retinal involvement in CLN3 disease compared to early-onset
STGD1. CLN3 disease and early-onset STGD1 present seemingly similar (A), but in-depth
analysis of ophthalmological test results performed around diagnosis reveals that the retinal
disease is in CLN3 disease already more extensive (B). In CLN3, more ocular components are
involved compared to STGD1: not only photoreceptors (cones and rods) but also inner retina and
optic nerve. In addition, the different components are more severely affected, for example a severe
cone involvement resulting in a severely impaired VA and severe colour vision deficiency around
diagnosis. VA, visual acuity; def, deficiency; RG, red-green.
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presenting clinical characteristics only.
This differentiation allows early identi-
fication of children with CLN3 disease
which is essential for adequate referral,
counselling and rehabilitation.
References
Anderson G, Smith VV, Malone M & Sebire
NJ (2005): Blood film examination for
vacuolated lymphocytes in the diagnosis of
metabolic disorders; retrospective experience
of more than 2,500 cases from a single
centre. J Clin Pathol 58: 1305–1310.
Audo I, Robson AG, Holder GE &Moore AT
(2008): The negative ERG clinical pheno-
types and disease mechanisms of inner
retinal dysfunction. Surv Ophthalmol 53:
16–40.
Bax NM, Lambertus S, Cremers FPM, Klev-
ering BJ & Hoyng CB (2019): The absence
of fundus abnormalities in Stargardt disease.
Graefes Arch Clin Exp Ophthalmol 257:
1147–1157.
Bohra LI, Weizer JS, Lee AG & Lewis RA
(2000): Vision loss as the presenting sign in
juvenile neuronal ceroid lipofuscinosis. J
Neuroophthalmol 20: 111–115.
Brouwer AH, de Wit GC, Ten Dam NH,
Wijnhoven R, van Genderen MM& de Boer
JH (2019): Prolonged cone b-wave on elec-
troretinography is associated with severity
of inflammation in non-infectious uveitis.
Am J Ophthalmol 207: 121–129.
Carelli V, Ross-Cisneros FN & Sadun AA
(2004): Mitochondrial dysfunction as a
cause of optic neuropathies. Progress in
retinal and eye research. Prog Retin Eye
Res 23: 53–89.
Dulz S, Wagenfeld L, Nickel M, Richard G,
Schwartz R, Bartsch U, Kohlsch€utter A &
Schulz A (2016): Novel morphological mac-
ular findings in juvenile CLN3 disease. Br J
Ophthalmol 100: 824–828.
Eksandh LB, Ponjavic VB, Munroe PB, Eiberg
HE, Uvebrant PE, Ehinger BE, Mole SE &
Andreasson S (2000): Full-field ERG in
patients with Batten/Spielmeyer-Vogt dis-
ease caused by mutations in the CLN3 gene.
Ophthalmic Genet 21: 69–77.
van Genderen MM, Riemslag F, Jorritsma F,
Hoeben F, Meire F & Stilma J (2006): The
key role of electrophysiology in the diagno-
sis of visually impaired children. Acta Oph-
thalmol Scand 84: 799–806.
Hainsworth DP, Liu GT, Hamm CW & Katz
ML (2009): Funduscopic and angiographic
appearance in the neuronal ceroid lipofusci-
noses. Retina 29: 657–668.
Hansen MS, Hove MN, Jensen H & Larsen M
(2016): Optical coherence tomography in
juvenile neuronal ceroid lipofuscinosis.
Retin Cases Brief Rep 10: 137–139.
Katz ML, Gao CL, Prabhakaram M, Shibuya
H, Liu PC & Johnson GS (1997): Immuno-
chemical localization of the Batten disease
(CLN3) protein in retina. Invest Ophthalmol
Vis Sci 38: 2375–2386.
Ku CA, Hull S, Arno G et al. (2017): Detailed
clinical phenotype and molecular genetic
findings in CLN3-associated isolated retinal
degeneration. JAMA Ophthalmol 135: 749–
760.
Kuper WFE, van Alfen C, van Eck L, van den
Broek BTA, Huisman A, van Genderen
MM & van Hasselt PM (2017): A case of
unexpected adult-onset neurologic decline in
CLN3-associated retinal degeneration.
JAMA Ophthalmol 135: 1451–1453.
Kuper WFE, van Alfen C, van Eck L, Huijgen
BCH, Nieuwenhuis EES, van Brussel M &
van Hasselt PM (2019): Motor function
impairment is an early sign of CLN3 disease.
Neurology 93: e293–e297.
Kuper WFE, van Alfen C, Rigterink RH, Fuchs
SA, van Genderen MM & van Hasselt PM
(2018): Timing of cognitive decline in CLN3
disease. J Inherit Metab Dis 41: 257–261.
Kuper WFE, Oostendorp M, van den Broek
BTA et al. (2020): Quantifying lymphocyte
vacuolization serves as a measure of CLN3
disease severity. JIMD Rep 54: 87–97.
Lambertus S, van Huet RA, Bax NM, Hoef-
sloot LH, Cremers FP, Boon CJ, Klevering
BJ & Hoyng CB (2015): Early-onset star-
gardt disease: phenotypic and genotypic
characteristics. Ophthalmology 122: 335–
344.
McCulloch DL, Marmor MF, Brigell MG,
Hamilton R, Holder GE, Tzekov R & Bach
M (2015): ISCEV standard for full-field
clinical electroretinography (2015 update).
Doc Ophthalmol 130: 1–12.
Mole SE & Cotman SL (2015): Genetics of the
neuronal ceroid lipofuscinoses (Batten dis-
ease). Biochim Biophys Acta 1852(10 Pt B):
2237–2241.
Nelson T, Pearce DA & Kovacs AD (2017):
Lack of specificity of antibodies raised
against CLN3, the lysosomal/endosomal
transmembrane protein mutated in juvenile
Batten disease. Biosci Rep 37: BSR20171229.
Ouseph MM, Kleinman ME & Wang QJ
(2016): Vision loss in juvenile neuronal
ceroid lipofuscinosis (CLN3 disease). Ann
N Y Acad Sci 1371: 55–67.
Preising MN, Abura M, J€ager M, Wassill KH
& Lorenz B (2017): Ocular morphology and
function in juvenile neuronal ceroid lipofus-
cinosis (CLN3) in the first decade of life.
Ophthalmic Genet 38: 252–259.
Robinson PN (2012): Deep phenotyping for
precision medicine. Hum Mutat 33: 777–
780.
Sappington RM, Pearce DA & Calkins DJ
(2003): Optic nerve degeneration in a murine
model of juvenile ceroid lipofuscinosis.
Invest Ophthalmol Vis Sci 44: 3725–3731.
Simunovic MP (2010): Colour vision defi-
ciency. Eye (Lond) 24: 747–755.
Snijders TAB & Bosker RJ (2012): Multilevel
Analysis: An Introduction to Basic and
Advanced Multilevel Modeling, 2nd edn.
Los Angeles, CA: SAGE Publications Inc.
Spalton DJ, Taylor DS & Sanders MD (1980):
Juvenile batten’s disease: an ophthalmolog-
ical assessment of 26 patients. Br J Ophthal-
mol 64: 726–732.
The International Batten Disease Consortium
(1995): Isolation of a novel gene underlying
Batten disease, CLN3. Cell 82: 949–957.
Wang F, Wang H, Tuan HF et al. (2014): Next
generation sequencing-based molecular
diagnosis of retinitis pigmentosa: identifica-
tion of a novel genotype-phenotype correla-
tion and clinical refinements. Hum Genet
133: 331–345.
Weimer JM, Custer AW, Benedict JW,
Alexander NA, Kingsley E, Federoff HJ,
Cooper JD & Pearce DA (2006): Visual
deficits in a mouse model of Batten disease
are the result of optic nerve degeneration
and loss of dorsal lateral geniculate thalamic
neurons. Neurobiol Dis 22: 284–293.
Wright GA, Georgiou M, Robson AG et al.
(2019): Juvenile Batten Disease (CLN3):
detailed ocular phenotype, novel observa-
tions, delayed diagnosis, masquerades, and
prospects for therapy. Ophthalmol. Retina
4: 433–445.
Received on June 5th, 2020.
Accepted on August 14th, 2020.
Correspondence:
Peter M. van Hasselt, MD, PhD
Wilhelmina Children’s Hospital




Tel: +31 88 75 540 01
Fax: +31 88 75 553 49
Email: P.vanhasselt@umcutrecht.nl
Willemijn F.E. Kuper receives unrestricted finan-
cial support from the Beat Batten Foundation, the
Friends of the Wilhelmina Children’s Hospital
Foundation and the Bartimeus foundation. The
funding organizations had no role in the design or
conduct of this research.
Supporting Information
Additional Supporting Information
may be found in the online version of
this article:
Table S1. Overview of ophthalmologi-
cal examinations* around presentation
in CLN3 disease and early-onset
STGD1.
Table S2. Overview of individual
CLN3 disease patients and early-onset
STGD1 patients examined around pre-
sentation at the Bartimeus Institute.
8
Acta Ophthalmologica 2020
